CATV yields 1333333.33% · ABBV yields 3.06%● Live data
📍 CATV pulled ahead of the other in Year 1
Combined, CATV + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CATV + ABBV for your $10,000?
4Cable TV International, Inc. provides specialty solutions to the cable television sector. It offers a suite of products comprising RF to Fiber (RF2F), a proprietary line of coax-to-fiber taps that enables cable operators to reach homes within their franchise authorized area; PowerMiser, a circuitry, which allows a low current 1 GHz amplifier and/or line extender to be constructed with a decrease in current power requirements; RF over Glass (RFoG) signal distribution technology that combines the existing cable TV infrastructure with fiber optics to reach the home; and Node+0 application, which combines the RFoG technology platform with its PowerMiser engineering to take fiber signal. The company also provides SOLAR-CATV that utilizes solar power and helps the operator extend service to areas not presently served without adding power sources; and Dynamically Scalable Return technology, which allows nodes, R-ONU's (RFoG optical network units) to adjust their return bandwidth by changing the channel lineup at the head end, as well as repair, testing, and upgrade services. It markets and sells its products through a network of dealers in the United States and Canada primarily to independent cable TV operators, as well as to multiple system operators. 4Cable TV International, Inc. was incorporated in 2007 and is based in Conway, South Carolina.
Full CATV Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.